https://www.selleckchem.com/pr....oducts/toyocamycin.h
62±1.75) was larger than the NRO group (1.89±0.97; p0.0001). At 1 and 6months, the MA density in the area with persistent oedema was significantly higher than in the area with improved oedema (1month p=0.0001, 6months p=0.029). High MA density and extensive swelling may be characteristic of RO following treatment for DMO with intravitreal injection of either aflibercept or ranibizumab. High MA density and extensive swelling may be characteristic of RO following treatment for DMO with intravitreal injection of either aflibercept
Like
Comment
Share
